SBI Healthcare Opportunities Fund Direct Plan Growth
Direct plan · Growth · Pharma and Healthcare · SBI Funds Management Private Limited
₹623.72
-₹4.35 (-0.69%) on the day
NAV on 16 Nov 2026. Mutual funds publish one NAV a day, after the market closes.
Near its 52-week high (-0.7%)
What stands out
| Return | 1 day | 1 week | 1 month | 3 months | 6 months | This year | 1 year | 3 years | 5 years | 10 years |
|---|---|---|---|---|---|---|---|---|---|---|
| This fund | -0.69% | -0.15% | +10.65% | +3.55% | +17.10% | +28.65% | +25.09% | +24.88% | +20.26% | +16.24% |
| In US dollarssame as UAE dirhams | - | - | - | - | - | - | +17.79% | +19.81% | +14.73% | +12.52% |
| BSE Healthcareto 13 Nov 2026 | -0.24% | +2.36% | +8.43% | +3.63% | +14.60% | +20.74% | +18.70% | +22.33% | +15.89% | +13.24% |
| Average of pharma and healthcare funds | - | - | +9.34% | +3.28% | +13.66% | +23.11% | +20.54% | +22.13% | +16.56% | - |
| Rank among them | - | - | 2/19 | 7/18 | 5/18 | 4/18 | 6/17 | 2/12 | 1/10 | - |
Returns from the plan's own NAVs to 16 Nov 2026. 3, 5 and 10 years are a yearly rate. Rank 1 is the best return; green is the top half, red the bottom half. Past performance does not indicate future returns.
If you had invested
You invest
₹6.00 L
60 months from Dec 2021
Worth today
₹10.77 L
+79.4%
₹10,000 at the start of every month, valued at the NAV of 16 Nov 2026. Before tax. Past performance does not indicate future returns.
Calendar years ahead of BSE Healthcare8 of 10
Where it ranks
among 19 pharma and healthcare funds, Direct plans1 year
6 of 17
Second quarter
3 years
2 of 12
Top quarter
5 years
1 of 10
Top quarter
Lowest cost
7 of 18
Second quarter
| Best over 3 years | 3 yr a year | Cost | Size |
|---|---|---|---|
| 1HDFC Pharma and Healthcare Fund | +30.9% | 1.03% | ₹3,501 Cr |
| 2SBI Healthcare Opportunities Fund this fund | +24.9% | 1.01% | ₹5,870 Cr |
| 3Mirae Asset Healthcare Fund | +23.9% | 0.62% | ₹3,494 Cr |
| 4UTI Healthcare Fund | +23.6% | 1.34% | ₹1,430 Cr |
| 5LIC MF Healthcare Fund | +21.9% | 1.37% | ₹99.36 Cr |
Every fund in the category computed from its own NAV the same way, to 16 Nov 2026. All Pharma and Healthcare funds ›
Fund details
52-week range of the NAV
-0.7% from the high of 12 Nov 2026
Fund size
₹5,870 Cr
Yearly cost (expense ratio)
1.01%
Regular plan 1.99%: ₹980 more a year on ₹1 lakh
Exit load
0.50% on or before 15D, Nil after 15D
Minimum SIP
₹500
Lump sum from ₹5,000
Risk level
Very High
Benchmark
BSE Healthcare
Fund manager
Tanmaya Desai
Launched
1 Jan 2013
Risk at a glance
Ups and downs (volatility), 3 years
14.4%
a year; BSE Healthcare 16.0%
Worst fall since launch
-30.5%
Oct 2015 to Mar 2020; back by Jun 2020
Worst calendar year
-12.9%
2016; best 2020 +67.7%
Months that ended up
69%
of the last 36 months
Against other pharma and healthcare funds, last 3 years (worst fall: 5 years)
Volatility
✓ 14.4%
Steadier than peers · average 15.9%
1 of 13
Worst fall
= -17.4%
In line with peers · average -18.2%
3 of 10
Sharpe ratio
✓ 1.31
More return for the risk · average 1.08
2 of 12
Yearly cost
= 1.01%
About average · average 1.10%
7 of 18
More measures ›Fewer measures ‹
Sharpe ratio, 3 years
1.31
Return above the CRISIL Overnight Index per unit of volatility
Sortino ratio, 3 years
2.75
The same, counting only falls
Alpha vs BSE Healthcare
+4.22%
Yearly return beyond what its beta explains
Beta vs BSE Healthcare
0.92
Moves this much when the index moves 1%
Share of the index's rises
101%
In months the index rose
Share of the index's falls
82%
In months the index fell; lower is better
Over the last 3 years, from the fund's NAVs against the BSE Healthcare.
Rolling returns
Every 3-year holding period, month by month, as a yearly rate
Made money
81%
of periods
Beat BSE Healthcare
95%
of periods
Worst
-7.9%
a year, to Oct 2018
Best
+36.2%
a year, to Jan 2016
This fund (solid) and BSE Healthcare (dashed): 131 periods from month-end NAVs. Past performance does not indicate future returns.
Compare rolling returns with other funds, in ₹, $ or AED ›
What it holds
34 holdings, as of Aug 2026- 1Sun Pharmaceutical Industries Ltd12.33%
- 2Divi'S Laboratories Ltd8.17%
- 3AMI Organics Ltd4.91%
- 4Apollo Hospitals Enterprises Ltd4.91%
- 5Torrent Pharmaceuticals Ltd4.72%
- 6Cipla Ltd4.67%
- 7Max Healthcare Institute Ltd4.31%
- 8Cash, TREPS and repo4.11%
- 9Laurus Labs Ltd3.96%
- 10Aurobindo Pharma Ltd3.90%
Show all 34 ›
- 11Aster Dm Healthcare Ltd3.52%
- 12Gland Pharma Ltd2.99%
- 13Anthem Biosciences Ltd2.90%
- 14Sudeep Pharma Ltd2.84%
- 15Fortis Healthcare Ltd2.82%
- 16Biocon Ltd2.67%
- 17Jupiter Life Line Hospitals Ltd2.55%
- 18SAI Life Sciences Ltd2.52%
- 19Concord Biotech Ltd2.40%
- 20Aether Industries Ltd2.33%
- 21Poly Medicure Ltd1.94%
- 22Global Health Ltd1.91%
- 23Ajanta Pharma Ltd1.86%
- 24Suven Pharmaceuticals Ltd1.73%
- 25Krishna Institute of Medical Sciences Ltd1.73%
- 26Mankind Pharma Ltd1.67%
- 27Dr. Lal Pathlabs Ltd1.47%
- 28Healthcare Global Enterprises Ltd1.27%
- 29Syngene International Ltd1.24%
- 30Nephrocare Health Services Ltd1.18%
- 31Rainbow Children'S Medicare Ltd0.73%
- 32Abbott India Ltd0.35%
- 33Gufic Biosciences Ltd0.29%
- 34364 DAY T-BILL 19.11.260.05%
Top 10: 56.0% of the fund. Check overlap with another fund ›
By company size
- Large cap32.3%
- Mid cap25.7%
- Small cap37.5%
- Other (cash, foreign, debt)4.5%
Shares by sector
- Healthcare94.5%
- Materials2.3%
- P/E of holdings
- 70.2
- Turnover a year
- 36%
Year by year
| Year | 2026 so far | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| This fund | +28.6% | -2.5% | +43.7% | +39.7% | -5.0% | +21.5% | +67.7% | +0.5% | -8.8% | +3.3% |
| BSE Healthcare | +20.7% | -3.3% | +43.5% | +37.0% | -12.1% | +20.9% | +61.4% | -3.5% | -5.9% | +0.5% |
| Average of pharma and healthcare funds | +23.5% | -2.7% | +43.0% | +38.0% | -8.6% | +22.0% | +68.9% | +5.3% | - | - |
SIP returns of pharma and healthcare funds · Fund returns in dollars · All pharma and healthcare funds · Fund screener
About SBI Healthcare Opportunities Fund Direct Plan Growth
SBI Healthcare Opportunities Fund Direct Plan Growth is a Sector Specific - Pharma equity fund from SBI Funds Management Private Limited, launched on 1 Jan 2013. Its benchmark is the BSE Healthcare Index. The expense ratio is 1.01% a year. It manages ₹5,870 crore. The NAV was ₹623.72 on 16 Nov 2026. Over 10 years it returned 16.24% a year in rupees and 12.52% a year in US dollars and UAE dirhams, as the rupee fell 3.31% a year against the dollar.
Questions about SBI Healthcare Opportunities Fund
What is the NAV of SBI Healthcare Opportunities Fund Direct Growth?
The NAV of SBI Healthcare Opportunities Fund Direct Growth was ₹623.72 on 16 Nov 2026. Mutual fund NAVs are published once a day, after markets close.
What are the returns of SBI Healthcare Opportunities Fund Direct Growth?
SBI Healthcare Opportunities Fund Direct Growth returned 25.1% over 1 year, 24.9% a year over 3 years, 20.3% a year over 5 years and 16.2% a year over 10 years, to 16 Nov 2026, worked out from its own daily NAV. It returned more than the BSE Healthcare Index in 9 of 10 calendar years since 2017.
What has SBI Healthcare Opportunities Fund returned in US dollars and UAE dirhams?
In US dollars it returned 17.8% over 1 year, 19.8% a year over 3 years, 14.7% a year over 5 years and 12.5% a year over 10 years. The rupee fell 3.3% a year against the dollar over 10 years, which accounts for the gap from the rupee return. The UAE dirham is pegged to the dollar, so returns in dirhams are the same.
What is the expense ratio of SBI Healthcare Opportunities Fund Direct Growth?
1.01% a year. It is taken from the fund's assets every day, so the NAV and every return shown are already after this cost.
Can NRIs in the UAE invest in SBI Healthcare Opportunities Fund?
NRIs can generally invest once KYC is complete, paying from an NRE or NRO account. SBI Mutual Fund accepts investors living in the US or Canada only on conditions, per its scheme documents checked on 15 Nov 2026. Rules change, so confirm with the fund house.
How are SBI Healthcare Opportunities Fund gains taxed for NRIs?
India taxes gains on equity funds at 20% on units held 12 months or less, and at 12.5% on gains above ₹1.25 lakh a year on units held longer, plus cess and any surcharge. For NRIs the tax is deducted when units are redeemed. The UAE has no personal income tax, and the India UAE tax treaty may apply, so confirm your position with a tax adviser.
Rolling returns in dollars shows every period, not just the latest.
Compare every pharma and healthcare fund on returns, volatility, worst fall and cost.






